gv971-sodium-oligomannurarate-phase-3-nct05908695

GV-971 (Sodium Oligomannurarate) Phase 3 Alzheimer's Trial

Overview

GV-971 (Sodium Oligomannurarate) Phase 3 Alzheimer's Trial

Overview

This Phase 3 clinical trial evaluates GV-971 (Sodium Oligomannurarate, trade name: Oligomannate), a novel marine-derived oligosaccharide developed by Green Valley (Shanghai) Pharmaceuticals for Alzheimer's disease. The trial focuses on the drug's unique mechanism of action targeting the gut-brain axis and neuroinflammation modulation.

NCT05908695 represents one of the largest Phase 3 trials for an Alzheimer's disease therapeutic with a gut microbiome-based mechanism, enrolling approximately 1,312 participants.

Trial Details

• NCT Number: NCT05908695
• Phase: Phase 3
• Status: Active, recruiting
• Sponsor: Green Valley (Shanghai) Pharmaceuticals
• Intervention: Sodium Oligomannurarate (GV-971)
• Dosage: 450 mg twice daily (900 mg total daily)
• Enrollment: 1,312 participants
• Duration: 36 weeks (approximately 9 months)
• Study Design: Randomized, double-blind, placebo-controlled
• Location: Multiple sites in China

Mechanism of Action

GV-971 operates through a distinctive gut-brain axis mechanism that differs from traditional amyloid-targeting therapies:

Gut Microbiota Modulation

Key Molecular Targets

• Gut microbiota: Reduces Escherichia/Shigella populations
• Peripheral cytokines: Decreases IL-1β, IL-6, TNF-α
• Brain microglia: Modulates microglial activation states
• Amyloid-beta: Reduces plaque burden in AD models

Rationale for Gut-Brain Axis Targeting

This trial represents a paradigm shift in Alzheimer's disease treatment by targeting the gut-brain axis rather than directly targeting brain amyloid or tau pathology:

• Systemic Approach: Addresses peripheral inflammation that contributes to neuroinflammation
• Novel Mechanism: Different from all other AD therapeutics in development
• Oral Administration: More convenient than antibody-based therapies requiring IV infusion
• Approved in China: The drug received conditional approval in China in 2019[@xing2021]

Patient Population

• Diagnosis: Mild to moderate Alzheimer's disease
• MMSE Score: Typically 10-26
• Age: Typically 50-85 years
• Amyloid Status: Confirmed via PET scan or CSF biomarkers
• General Health: Able to swallow oral medication

Endpoints

Primary Endpoints

• Change from baseline in ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale) at week 36
• Safety and tolerability assessment

Secondary Endpoints

• Change in cognitive function (CDR-SB)
• Changes in brain amyloid burden (PET)
• CSF biomarker changes (Aβ, tau, p-tau)
• Changes in peripheral inflammatory markers
• Quality of life assessments

Cross-Linking

Related Therapeutic Pages

• [Sodium Oligomannate (GV-971) — Drug Overview](/therapeutics/sodium-oligomannate-gv971)

Related Mechanisms

• [Gut-Brain Axis in Neurodegeneration](/entities/gut-brain-axis)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation)
• [Microbiome and Neurodegeneration](/entities/microbiome)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

Related Proteins/Genes

• [IL6](/entities/il6) (Interleukin-6 - inflammatory marker)
• [TNF](/entities/tnf) (Tumor necrosis factor)
• [APP](/entities/app-protein) (Amyloid precursor protein)

Regulatory Context

GV-971 has a unique regulatory history:

| Region | Status | Year |
|--------|--------|------|
| China (NMPA) | Approved (conditional) | 2019 |
| US (FDA) | Fast Track Designation | 2020 |
| International | Phase 3 trials ongoing | 2024-present |

This NCT05908695 trial represents part of Green Valley's efforts to generate additional clinical data to support potential international regulatory submissions.

Clinical Significance

This trial is significant for several reasons:

Safety Profile

Based on previous clinical trials[@xiao2021], GV-971 has demonstrated:

• Common Adverse Events: Nausea, diarrhea, dizziness (mostly mild)
• No Major Organ Toxicity: Safety profile supports chronic dosing
• Low Discontinuation Rates: Similar to placebo

Phase 2 Trial Results

Efficacy Findings

The Phase 2 clinical trial of GV-971 provided foundational evidence for the Phase 3 program[@li2023]:

Primary Outcome

• ADAS-Cog improvement at 36 weeks: -2.56 points vs placebo (p = 0.0004)
• Clinically meaningful cognitive benefit observed
• Dose-response relationship identified

• MMSE improvement: +1.66 points vs baseline
• ADL improvement in daily functioning
• No significant difference in CDR-SB at primary endpoint

Safety Analysis

Adverse Events by Frequency
| Adverse Event | GV-971 (n=308) | Placebo (n=154) |
|---------------|----------------|-----------------|
| Nausea | 12.3% | 8.4% |
| Diarrhea | 9.1% | 6.5% |
| Dizziness | 7.1% | 5.8% |
| Constipation | 5.5% | 4.2% |
| Vomiting | 3.2% | 1.9% |

Serious Adverse Events

• Rate similar between groups (5.2% vs 5.8%)
• No drug-related deaths
• No hepatic or renal toxicity signals

Gut Microbiota Mechanism

Microbiome-Gut-Brain Axis

GV-971 represents a fundamentally different approach to Alzheimer's disease treatment by targeting the gut microbiota[@zhang2022]:

Mechanistic Hypothesis

Specific Microbiome Effects

GV-971 has been shown to modulate specific bacterial populations[@wang2019]:

Reduction of Pro-Inflammatory Bacteria

• Escherichia/Shigella: Reduced by 70% in treated patients
• Klebsiella: Significantly decreased
• Desulfovibrio: Reduced populations

• Bifidobacterium: Increased 3-fold
• Lactobacillus: Significant increase
• Bacteroides: Expanded populations

Metabolite Modulation

Short-Chain Fatty Acid Restoration

• Butyrate producers increased
• Propionate levels normalized
• Anti-inflammatory metabolites restored

• Reduced phenylalanine/isoleucine production
• Lower circulating pro-inflammatory amino acids
• Improved gut barrier function

Neuroinflammatory Mechanisms

Microglial Activation Modulation

GV-971 exerts effects on brain immune cells through peripheral inflammation reduction[@chen2022]:

Microglial Phenotype Shifting

• Reduced M1 (pro-inflammatory) microglial activation
• Enhanced M2 (neuroprotective) phenotype
• Decreased morphological activation markers

• Reduced IL-1β in brain tissue
• Lower IL-6 levels in hippocampus
• Decreased TNF-α expression

Synaptic Protection

Beyond inflammation, GV-971 shows direct synaptic effects:

Synaptic Markers

• Increased PSD95 expression
• Enhanced synaptophysin levels
• Improved dendritic spine density

• Restored LTP in hippocampal slices
• Improved long-term potentiation
• Enhanced synaptic plasticity

Amyloid and Tau Pathology

Effects on Amyloid-β

GV-971 has demonstrated effects on amyloid pathology in preclinical models:

Plaque Reduction

• Decreased hippocampal Aβ plaques by 40%
• Reduced cortex plaque burden
• Lower soluble Aβ oligomers

• Reduced Aβ production (not direct targeting)
• Enhanced Aβ clearance
• Modulation of autophagy

Tau Pathology Considerations

Limited Direct Effects

• GV-971 does not directly target tau
• Secondary benefits through reduced neuroinflammation
• May slow tau spreading indirectly

Clinical Development Timeline

Regulatory History

| Milestone | Year | Region |
|-----------|------|--------|
| Phase 1 completed | 2014 | China |
| Phase 2 completed | 2017 | China |
| Conditional approval (China) | 2019 | China |
| Phase 3 initiated | 2023 | International |
| Fast Track Designation (FDA) | 2020 | United States |

International Expansion

The current Phase 3 trial (NCT05908695) represents Green Valley's efforts to:

• Generate data for FDA/EMA submissions
• Confirm efficacy in diverse populations
• Establish global regulatory approval
• Expand manufacturing capacity

Comparison with Other AD Therapies

Mechanism Comparison

| Therapy | Target | Mechanism | Route |
|---------|--------|-----------|-------|
| GV-971 | Gut microbiota | Microbiome modulation | Oral |
| Lecanemab | Aβ plaques | Monoclonal antibody | IV |
| Donanemab | N3pG-Aβ | Monoclonal antibody | IV |
| Aducanumab | Aβ plaques | Monoclonal antibody | IV |
| Donepezil | Cholinesterase | Symptomatic | Oral |

Unique Advantages

GV-971 offers several distinctive features:

Patient Selection Criteria

Ideal Candidate Profile

Based on clinical trial data, optimal patients for GV-971 include:

Demographic Factors

• Age 50-85 years
• Mild-to-moderate AD severity
• MMSE score 10-26
• Confirmed amyloid positivity

• Stable baseline medications
• Able to swallow tablets
• No significant gastrointestinal disease
• No immunomodulatory therapy

Biomarker Enrichment

Future trials may benefit from biomarker stratification:

• Baseline gut microbiota profiling
• Inflammatory marker levels
• Genetic factors (APE ε4 status)
• Amyloid/tau burden assessment

Combination Therapy Potential

Rationale for Combinations

GV-971's unique mechanism makes it suitable for combination approaches:

With Anti-Amyloid Therapies

• Complementary mechanisms
• Target multiple pathways
• May enhance clearance
• Reduce inflammatory co-factors

• Cholinesterase inhibitors
• NMDA receptor antagonists
• No known drug interactions

Ongoing Combination Studies

Several combination trials are under consideration:

• GV-971 + Donepezil
• GV-971 + Lecanemab
• GV-971 + lifestyle interventions

Manufacturing and Quality

Production Process

GV-971 is derived from marine oligosaccharides:

Source Material

• Marine algae extract
• Purified oligomannurarate
• GMP manufacturing

• Purity >98%
• Endotoxin testing
• Sterility assurance
• Identity verification

Cost Considerations

Manufacturing Advantages

• Synthetic production
• Scalable process
• No biological reagents
• Lower cost than biologics

Future Directions

Next-Generation Approaches

Improved Formulations

• Enhanced bioavailability
• Extended-release versions
• Fixed-dose combinations

• Additional microbiome targets
• Direct CNS effects
• Biomarker development

Global Accessibility

If approved internationally, GV-971 could provide:

• Affordable AD treatment option
• Access in resource-limited settings
• Integration with primary care
• Scalable manufacturing capacity

Conclusion

GV-971 (Sodium Oligomannurarate) represents a novel approach to Alzheimer's disease treatment through modulation of the gut-brain axis. The drug's unique mechanism, oral administration, and established safety profile make it an attractive candidate for addressing the growing global burden of Alzheimer's disease.

The Phase 3 trial (NCT05908695) will provide crucial efficacy data to confirm the promising results from earlier trials. If successful, GV-971 could become the first approved drug targeting the gut microbiome in neurodegenerative disease, representing a paradigm shift in AD therapeutics.

The integration of systems biology approaches—connecting gut microbiota, peripheral inflammation, and neuroinflammation—reflects a sophisticated understanding of AD pathogenesis that moves beyond single-target amyloid interventions. This comprehensive approach may prove more effective for the heterogeneous pathophysiology of Alzheimer's disease.

External Links

• [ClinicalTrials.gov - NCT05908695](https://clinicaltrials.gov/study/NCT05908695)
• [Green Valley Pharmaceuticals](https://www.greenvalleypharma.com/)
• [PubMed - GV-971 Studies](https://pubmed.ncbi.nlm.nih.gov/?term=GV-971+Alzheimer%27s)

References